{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:34:14Z","timestamp":1788986054090,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Patients who require prolonged intravenous antibiotics for Staphylococcus aureus bacteremia (SAB) and who are ineligible for outpatient parental antibiotic therapy (OPAT) present a challenge in regard to delivering appropriate and cost-effective treatment. Oritavancin, a novel long-acting lipoglycopeptide, shows promise as an alternative to OPAT for patients with complex Gram-positive infections, including those with SAB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the outcomes, including safety and impact on length of stay and cost-effectiveness of using oritavancin for patients with SAB who are ineligible for OPAT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective single-arm cohort study of adult patients with SAB who received at least 1 dose of oritavancin within the Hunter New England Local Health District between January 2020 and July 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 27 patients were identified: mean age, 43 years, 52% male, and 59% people who currently inject drugs. Sources\/foci of infection included bone\/joint infection (26%), skin\/soft-tissue infection (15%), infective endocarditis (26%), catheter-associated bacteremia (7%), and bacteremia with no clear source\/focus (26%). Intravenous antibiotics were administered for a mean duration of 10 days before oritavancin therapy. Clinical cure was seen in 26\/27 (96%) of patients, with 1 patient lost to follow-up and deemed not clinically evaluable. Twenty-four of 27 (89%) patients were alive at the end of the 180-day follow-up period, with 2 patient deaths unrelated to their index infection and 1 patient not clinically evaluable. A total of 89% of patients demonstrated a positive return on investment, with on average 18 hospital days per patient avoided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Oritavancin is promising as a suitable and potentially cost-effective alternative for patients with SAB who are ineligible for OPAT. Prospective studies are required to confirm its utility in clinical practice, in particular in patients who do not receive oral antibiotic stepdown therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf333","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:37:35Z","timestamp":1749742655000},"source":"Crossref","is-referenced-by-count":7,"title":["Oritavancin for the Treatment of <i>Staphylococcus aureus<\/i> Bacteremia\u2014A Retrospective Single-arm Cohort Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3640-3733","authenticated-orcid":false,"given":"H","family":"Jordan","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, John Hunter Hospital , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kozierowski","sequence":"additional","affiliation":[{"name":"Pharmacy Department, John Hunter Hospital , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-499X","authenticated-orcid":false,"given":"R","family":"Pickles","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, John Hunter Hospital , Newcastle ,","place":["Australia"]},{"name":"School of Medicine and Public Health, University of Newcastle , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, John Hunter Hospital , Newcastle ,","place":["Australia"]},{"name":"School of Medicine and Public Health, University of Newcastle , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025100812575512500_ofaf333-B1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025100812575512500_ofaf333-B2","author":"Directed therapy for bloodstream infections, including sepsis and septic shock: therapeutic guidelines"},{"key":"2025100812575512500_ofaf333-B3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciac714","article-title":"Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs","volume":"76","author":"Wildenthal","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025100812575512500_ofaf333-B4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025100812575512500_ofaf333-B5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"2025100812575512500_ofaf333-B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","article-title":"Clinical outcomes and economic impact of oritavancin for Gram-positive infections: a single academic medical center health system experience","volume":"7","author":"Brownell","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2025100812575512500_ofaf333-B7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40360-020-00452-z","article-title":"Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs","volume":"21","author":"Ahiskali","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"Suppl 1","key":"2025100812575512500_ofaf333-B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2025100812575512500_ofaf333-B9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2025100812575512500_ofaf333-B10","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2025100812575512500_ofaf333-B11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025100812575512500_ofaf333-B12","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-015-0478-7","article-title":"Oritavancin: a review in acute bacterial skin and skin structure infections","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs"},{"key":"2025100812575512500_ofaf333-B13","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025100812575512500_ofaf333-B14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100812575512500_ofaf333-B15","first-page":"143","article-title":"Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections","volume":"43","author":"Rosenthal","year":"2018","journal-title":"P T"},{"key":"2025100812575512500_ofaf333-B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-26078-0","volume-title":"New antimicrobials: for the present and future","author":"Fong","year":"2023"},{"key":"2025100812575512500_ofaf333-B17","author":"Turner"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf333\/63480347\/ofaf333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf333\/63480347\/ofaf333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf333\/63480347\/ofaf333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:59:20Z","timestamp":1759942760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf333\/8161185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf333","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,12]]},"article-number":"ofaf333"}}